Evidence map›Paper›PMID 22155653›Full record

ArticleNeuroscience2012

Increased cholecystokinin labeling in the hippocampus of a mouse model of epilepsy maps to spines and glutamatergic terminals.

M S Wyeth, N Zhang, C R Houser

Abstract read
In one paragraph

Article in Neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Postsynaptic Depolarization Enhances GABA Drive to Dorsomedial Hypothalamic Neurons through Somatodendritic Cholecystokinin Release.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

M S WyethDepartment of Neurobiology, CHS 73-235, David Geffen School of Medicine at the University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1763, USA.
N Zhang
C R Houser
University of California, Los Angeles · US

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
GABA Neurons and EpilepsyR01NS046524 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOUSER, CAROLYN R · 2003 to 2007
$1.6M
GABA Receptor Subunit Plasticity in EpilepsyR01NS051311 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOUSER, CAROLYN R · 2005 to 2008
$1.4M
GABA Receptor Subunit Plasticity in EpilepsyR56NS051311 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOUSER, CAROLYN R · 2010 to 2010
$385k
Neuronal Loss and Plasticity in EpilepsyI01BX000404 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI HOUSER, CAROLYN R · 2011 to 2013
–
BLRD VA I01 BX000404NIDDK NIH HHS DK41301NIDDK NIH HHS P30 DK041301NINDS NIH HHS NS046524NINDS NIH HHS NS051311NINDS NIH HHS R01 NS046524NINDS NIH HHS R01 NS051311NINDS NIH HHS R56 NS051311
6 · The paper itself

Abstract

The neuropeptide cholecystokinin (CCK) is abundant in the CNS and is expressed in a subset of inhibitory interneurons, particularly in their axon terminals. The expression profile of CCK undergoes numerous changes in several models of temporal lobe epilepsy. Previous studies in the pilocarpine model of epilepsy have shown that CCK immunohistochemical labeling is substantially reduced in several regions of the hippocampal formation, consistent with decreased CCK expression as well as selective neuronal degeneration. However, in a mouse pilocarpine model of recurrent seizures, increases in CCK-labeling also occur and are especially striking in the hippocampal dendritic layers of strata oriens and radiatum. Characterizing these changes and determining the cellular basis of the increased labeling were the major goals of the current study. One possibility was that the enhanced CCK labeling could be associated with an increase in GABAergic terminals within these regions. However, in contrast to the marked increase in CCK-labeled structures, labeling of GABAergic axon terminals was decreased in the dendritic layers. Likewise, cannabinoid receptor 1-labeled axon terminals, many of which are CCK-containing GABAergic terminals, were also decreased. These findings suggested that the enhanced CCK labeling was not due to an increase in GABAergic axon terminals. The subcellular localization of CCK immunoreactivity was then examined using electron microscopy, and the identities of the structures that formed synaptic contacts were determined. In pilocarpine-treated mice, CCK was observed in dendritic spines and these were proportionally increased relative to controls, whereas the proportion of CCK-labeled terminals forming symmetric synapses was decreased. In addition, CCK-positive axon terminals forming asymmetric synapses were readily observed in these mice. Double labeling with vesicular glutamate transporter 1 and CCK revealed colocalization in numerous terminals forming asymmetric synapses, confirming the glutamatergic identity of these terminals. These data raise the possibility that expression of CCK is increased in hippocampal pyramidal cells in mice with recurrent, spontaneous seizures.

Indexed as

AnimalsCA1 Region, HippocampalCholecystokininDendritic SpinesEpilepsyExcitatory Postsynaptic PotentialsFluorescent Antibody TechniqueGlutamic AcidHippocampusImmunoenzyme TechniquesImmunohistochemistryMiceMice, Inbred C57BLMicroscopy, ConfocalMicroscopy, ElectronPilocarpineCholecystokininGlutamic AcidPilocarpineReceptor, Cannabinoid, CB1Scopolamine

Identifiers

PMID22155653
PMCPMC3268850
OpenAlexW1987985785

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.